Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Preferred Stock Liabilities (2020)

Palisade Bio (PALI) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $9.5 million as the latest value for Q4 2020.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $9.5 million in Q4 2020 year-over-year; TTM through Dec 2020 was $9.5 million, a N/A change, with the full-year FY2020 number at $9.5 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $9.5 million for Q4 2020 at Palisade Bio.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $9.5 million in Q4 2020 to a low of $9.5 million in Q4 2020.